CPMV (Mosaic ImmunoEngineering) Operating Income : $-0.88 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Operating Income?

Mosaic ImmunoEngineering's Operating Income for the three months ended in Dec. 2024 was $-0.15 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.88 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Mosaic ImmunoEngineering's Operating Income for the three months ended in Dec. 2024 was $-0.15 Mil. Mosaic ImmunoEngineering's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Mosaic ImmunoEngineering's Operating Margin % for the quarter that ended in Dec. 2024 was %.

Mosaic ImmunoEngineering's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mosaic ImmunoEngineering's annualized ROC % for the quarter that ended in Dec. 2024 was -15.13%. Mosaic ImmunoEngineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was %.

Mosaic ImmunoEngineering Operating Income Historical Data

The historical data trend for Mosaic ImmunoEngineering's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Operating Income Chart

Mosaic ImmunoEngineering Annual Data

Trend

May15

May16

May17

May18

May19

May20

Dec21

Dec22

Dec23

Dec24

Operating Income

Get a 7-Day Free Trial

-1.00

-3.50

-2.63

-1.40

-0.88

Mosaic ImmunoEngineering Quarterly Data
	Feb20	May20	Aug20	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Operating Income	Get a 7-Day Free Trial															-0.28	-0.27	-0.27	-0.19	-0.15

Mosaic ImmunoEngineering Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88 Mil.

Mosaic ImmunoEngineering (OTCPK:CPMV) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mosaic ImmunoEngineering's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-0.6 * ( 1 - -1.32% )	/	( (3.893	+	4.145)	/ 2 )
=	-0.60792	/	4.019
=	-15.13 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.04	-	1.408	-	( 0.006	-	max(0, 5.301	-	0.04	+	0.006	))
=	3.893

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.142	-	1.392	-	( 0.115	-	max(0, 5.537	-	0.142	+	0.115	))
=	4.145

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Mosaic ImmunoEngineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.516	/	( ( (0 + max(-5.193, 0))	+	(0 + max(-5.31, 0)) )	/	2 )
=	-0.516	/	( ( 0	+	0 )	/	2 )
=	-0.516	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.034)	-	(1.408	+	0	+	3.819)
=	-5.193

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.027)	-	(1.392	+	0	+	3.945)
=	-5.31

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Mosaic ImmunoEngineering's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-0.15	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Mosaic ImmunoEngineering Operating Income Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Mosaic ImmunoEngineering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646

Website

https://www.mosaicie.com

Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.

Executives

Robert Baffi	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University	10 percent owner	10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King	director, officer: President and CEO
Paul J Lytle	director, officer: EVP, Chief Financial Officer
Robert L Garnick	director	C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz	director, officer: Chief Scientific Officer	871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry	director	315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson	director
Donald E Schrock	director	C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau	officer: VP, Business Development	MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner	officer: Chief Executive Officer	MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers	officer: Chief Financial Officer	C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick	director	6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney	officer: CFO
Helmut Jr Falk	director